The use of biomarkers is of ever-increasing importance in clinical diagnosis of disease. In practice, a cutpoint is required for dichotomizing naturally continuous biomarker levels to distinguish persons at risk of disease from those who are not. Two methods commonly used for establishing the ''optimal'' cutpoint are the point on the receiver operating characteristic curve closest to (0,1) and the Youden index, J. Both have sound intuitive interpretations-the point closest to perfect differentiation and the point farthest from none, respectively-and are generalizable to weighted sensitivity and specificity. Under the same weighting of sensitivity and specificity, these two methods identify the same cutpoint as ''optimal'' in certain situations but different cutpoints in others. In this paper, the authors examine situations in which the two criteria agree or disagree and show that J is the only ''optimal'' cutpoint for given weighting with respect to overall misclassification rates. A data-driven example is used to clarify and demonstrate the magnitude of the differences. The authors also demonstrate a slight alteration in the (0,1) criterion that retains its intuitive meaning while resulting in consistent agreement with J. In conclusion, the authors urge that great care be taken when establishing a biomarker cutpoint for clinical use.
The proper diagnosis of disease and treatment administration is a task that requires a variety of tools. Through advancements in biology and laboratory methods, a multitude of biomarkers are available as clinical tools for such diagnosis. These biomarkers are usually measured on a continuous scale with overlapping levels for diseased and nondiseased persons. Cutpoints dichotomize biomarker levels, providing benchmarks that label people as diseased or not diseased on the basis of ''positive'' or ''negative'' test results. Biomarker levels of persons with known disease status are used to evaluate potential cutpoint choices and, hopefully, identify a cutpoint that is ''optimal'' under some criterion.
Such a data set would comprise biomarker levels for persons classified as coming from the diseased (D) or nondiseased ( D) population. These levels could then be classified in terms of positive (þ) or negative (ÿ) test results on the basis of whether the biomarker levels were above or below a given cutpoint. In most instances, some persons will be misclassified, truly belonging to a population other than the one indicated by their test results. The sensitivity (q(c)) and specificity (p(c)) of that biomarker for a given cutpoint, c, are the probabilities of correctly identifying a person's disease status (i.e., identifying true positives and true negatives):
making 1 minus these values the probability of incorrect classification or of obtaining false negatives (1 ÿ q(c)) and false positives (1 ÿ p(c)).
A receiver operating characteristic (ROC) curve is a mapping of this sensitivity by 1 minus specificity. The ROC curve has become a useful tool in comparing the effectiveness of different biomarkers (1) (2) (3) . This comparison takes place through summary measures such as the area under the curve (AUC) and the partial AUC, with higher area values indicating higher levels of diagnostic ability (1, 2, 4) . A biomarker with an AUC of 1 differentiates perfectly between diseased persons (sensitivity ¼ 1) and healthy persons (specificity ¼ 1). An AUC of 0.5 means that, overall, there is a 50-50 chance that the biomarker will correctly identify diseased or healthy persons as such.
Though useful for biomarker evaluation, these measures do not inherently lead to benchmark ''optimal'' cutpoints with which clinicians and other health-care professionals can differentiate between diseased and nondiseased persons. Several methods for identifying ''optimal'' cutpoints using sensitivity, specificity, and the ROC curve have been proposed and applied (4) (5) (6) (7) (8) . Confidence intervals and corrections for measurement error are some of the supporting statistical developments accompanying cutpoint estimation (9) . Applications of these techniques have been demonstrated in several fields, including nuclear cardiology, epidemiology, and genetics (7, 10, 11) .
In the ''Criteria'' section of this article, we describe two criteria for locating this cutpoint that have similar intuitive justifications. In describing the mathematical mechanisms behind these criteria, we demonstrate that one of the criteria retains the intended meaning, while the other inherently depends on quantities that may differ from an investigator's intentions. In the ''Example'' section, we use data from a nested case-control study carried out in the Calcium for Pre-Eclampsia Prevention cohort (12) to demonstrate how these two criteria identify different cutpoints for the classification of 120 preeclampsia cases and 120 controls based on levels of placenta growth factor, a biomarker of angiogenesis. Next, we discuss the appropriateness of the term ''optimal'' as it applies to each criterion. This is handled first with equally weighted sensitivity and specificity. Consideration of differing disease prevalences and costs due to misclassification is also presented as a practical generalization (5, 13) . We end with a brief discussion.
CRITERIA
The closest-to-(0,1) criterion If a biomarker perfectly differentiates persons with disease from those without disease on the basis of a single cutpoint, where q(c) ¼ 1 and p(c) ¼ 1, the ROC curve is a vertical line from (0,0) to (0,1) joined with a line from (0,1) to (1,1) with an AUC of 1. However, for a less-thanperfect biomarker, where q(c) < 1 and/or p(c) < 1, the ROC curve does not touch the (0,1) point. Here the choice of an ''optimal'' cutpoint is less straightforward. A criterion by which the point on the curve closest to (0,1) is identified and the corresponding cutpoint is labeled ''optimal'' has been suggested and utilized (6, 7) . The rationale behind this approach is that the point on the curve closest to perfection (i.e., closest to q(c) ¼ 1 and p(c) ¼ 1) should correspond to the optimal cutpoint chosen from all of the cutpoints available, thus intuitively minimizing misclassification. Mathematically, the point c* that satisfies the equation
fulfills this criterion and is thus labeled the cutpoint that best differentiates between diseased and nondiseased persons. This criterion can be viewed as searching for the shortest radius originating at the (0,1) point and terminating on the ROC curve. Reference arcs can be used to visually compare radial distances, with the arc corresponding to c* being tangent to the ROC curve and thus the minimum and interior of any of the concentric arcs possible. Figure 1 demonstrates this point at which the dotted arc is completely interior to, and thus closer to (0,1) than, the arc formed by the distance to an alternate point on the curve.
The Youden index
Another measure for evaluating biomarker effectiveness is the Youden index (J), first introduced in the medical literature by Youden (14) . J is also a function of q(c) and p(c), such that over all cutpoints c, with c J denoting the cutpoint corresponding to J. On a ROC curve, J is the maximum vertical distance from the curve to the chance line or positive diagonal (figure 1), making c J the ''optimal'' cutpoint (5, 15) . The intuitive interpretation of the Youden index is that J is the point on the curve farthest from chance. It has also been defined as the accuracy of the test in clinical epidemiology (16) .
Agreement/disagreement
The above criteria agree with respect to intuition; they maximize and minimize the rates of people's being classified correctly and incorrectly, respectively. The question ''Do they agree on the same 'optimal' cutpoint?'' now begs to be answered.
Suppose the biomarker of interest follows continuous distributions for both diseased and nondiseased populations that are known completely, leading to a true ROC curve. Our only distributional restriction is that a ROC curve is generated that is differentiable everywhere. This is intrinsic to the case where diseased and nondiseased persons are assumed to follow any number of common continuous densities (i.e., normal, lognormal, gamma, etc.). Through differentiation, Appendix 1 shows that the two criteria only agree, c* ¼ c J ¼ c, when q(c*) ¼ p(c*) and q(c J ) ¼ p(c J ). When either criterion identifies a point on the curve such that q(c*) 6 ¼ p(c*) or q(c J ) 6 ¼ p(c J ), the criteria disagree on what cutpoint is ''optimal,'' that is, c* 6 ¼ c J .
An investigator with complete knowledge of a biomarker's data distribution could be faced with two different cutpoints labeled ''optimal'' under two criteria that are intuitively the same. Our motivation here is simply to show that they are different and address the appropriateness of the label ''optimal.''
EXAMPLE
Preeclampsia affects approximately 5 percent of pregnancies, resulting in substantial maternal and neonatal morbidity and mortality (16) . Although the cause remains unclear, the syndrome may be initiated by placental factors that enter the maternal circulation and cause endothelial dysfunction, resulting in hypertension and proteinuria (12) . Identifying women suffering from preeclampsia is a very important step in the management of the disease. Placenta growth factor is a promising biomarker for such classification, with an AUC of 0.60 (95 percent confidence interval: 0.53, 0.67); however, at what level would a woman be classified as at risk for the disease? Levine et al. (12) conducted a nested casecontrol study of 120 women with preeclampsia and 120 normal women randomly chosen from the Calcium for Pre-Eclampsia Prevention cohort study. Placenta growth factor levels were measured from serum specimens obtained before labor. Figure 2 shows the ROC curve generated from the log-transformed placenta growth factor levels. After calculation of the distance to (0,1) and the distance to the diagonal for each point, the cutpoints c* ¼ 4.64 and c J ¼ 4.12, respectively, are identified. Thus, criteria with seemingly identical intuitive intents produce close results but disagree on the ''optimal'' cutpoint. Again, here it is sufficient to demonstrate that disagreement exists. We will revisit this example after the question of ''optimality'' has been addressed.
''Optimality''
When attempting to classify people on the basis of biomarker levels, it is always one's intent to do so ''optimally.'' However, the event of interest may intrinsically involve constraints which must, for ethical or fiscal reasons, be considered. These constraints commonly account for the prevalence of the event in both populations and the costs of misclassification, both monetary and physiologic. Thus, mathematical techniques of optimality must now operate within these constraints, but the idea of an ''optimal'' cutpoint should remain; one still wishes to choose a point that classifies the most people correctly and the fewest incorrectly.
First let us assume the simplest scenario, absent of constraints or weighting. By definition, the c J found by equation 2 succeeds ideologically by maximizing the overall rate of correct classification, q(c J ) þ p(c J ). As a result, the overall rate of misclassification, (1 ÿ q(c J )) þ (1 ÿ p(c J )), is minimized. Thus, we can say that c J is ''optimal'' with respect to the total correct and incorrect classification rates and any cutpoint that deviates from it is not. Under the same scenario, the closest-to-(0,1) criterion in equation 1 minimizes the total squared misclassification rates, quadratic terms for which an ideology does not seem to exist, other than being geometrically intuitive.
to show that this criterion minimizes the total of the misclassification rates and a third term, the average of squared correct classification rates. Unless a specific justification for this third term exists, its usage results in unwarranted and thus unnecessary misclassification, because it identifies a point c* 6 ¼ c J . Now, let us consider the circumstance in which cost and prevalence are thought to be factors, as they usually are in practice. Using decision theory, a generalized J can be formed where these factors are represented as a weighting of sensitivity and specificity. The function that minimizes expected loss in classifying a subject can be written as
where a denotes the relative loss (cost) of a false-negative classification as compared with a false-positive classification and p is the proportion of diseased persons in the population of interest (prevalence) (17, 18) . It is easy to see that minimizing this expected loss over all possible threshold values is the same as
where r ¼ (1 ÿ p)/ap. For r ¼ 1, this is equivalent to J. Weighting of the (0,1) criterion occurs similarly, minfð1 ÿ qðcÞÞ 2 þ r 3 ð1 ÿ pðcÞÞ
where r is exactly the same weighting estimate for cost and prevalence. The issue of the quadratic term remains minfð1 ÿ qðcÞÞ þ r 3 ð1 ÿ pðcÞÞ þ ðqðcÞ 2 þ r 3 pðcÞ 2 Þ=2g; ð7Þ only now it is weighted and unnecessary. Comparing this equation to equation 4, it is easy to see that this absolutely does not minimize loss due to misclassification.
Example revisited
To demonstrate this unnecessary misclassification and its possible magnitude, we revisit the example of placenta growth factor levels' being used to differentiate preeclamptic women from those without the disease. Sensitivity and specificity at the cutpoints previously identified are q(c*) ¼ 0.592, p(c*) ¼ 0.558 and q(c J ) ¼ 0.817, p(c J ) ¼ 0.358, respectively. The overall correct classification rate (q þ p) is 1.150 for c* and 1.175 for c J out of a possible 2, with a difference of 0.025. Without the justification for the third term in equation 3 and without weighting, this difference can be thought of as one person out of 100 being unnecessarily misclassified. Relative cost and disease prevalence are often difficult to assess, as discussed by Greiner et al. (18) and the references cited therein. Thus, we will not attempt adjustment in this example.
DISCUSSION
In this paper, we demonstrated the intuitive similarity of two criteria used to choose an ''optimal'' cutpoint. We then showed that the criteria agree in some instances and disagree in others. Placenta growth factor levels used to classify women as preeclamptic or not preeclamptic were used to demonstrate this point and quantify the extent of disagreement.
We addressed both criteria in the context of what an investigator might view as ''optimal,'' with and without attention to misclassification cost and prevalence. Mathematically, J reflects the intention of maximizing overall correct classification rates and thus minimizing misclassification rates, while choosing the point closest to (0,1) involves a quadratic term for which the clinical meaning is unknown. It is for this reason that we advocate for the use of J to find the ''optimal'' cutpoint.
Since the (0,1) criterion is visually intuitive, we have provided an amended (0,1) criterion in Appendix 2 that is likewise geometrically satisfying while consistently identifying the same ''optimal'' cutpoint as J. This criterion relies on a ratio of radii originating at (0,1).
Additional motivation for using J is an ever-increasing body of supporting literature (9, 15, 19) . Topics such as confidence intervals and correcting the estimate for measurement error have been considered, whereas the (0,1) criterion lacks such support.
Most importantly, cutpoints chosen through less than ''optimal'' criteria or criteria that are ''optimal'' in some arbitrary sense can lead to unnecessary misclassifications, resulting in needlessly missed opportunities for disease diagnosis and intervention. We showed above that J is ''optimal'' when equal weight is given to sensitivity and specificity, r ¼ 1, and a generalized J is ''optimal'' when cost and prevalence lead to weighted sensitivity and specificity, r 6 ¼1. Thus, when the point closest to (0,1) differs from the point resulting in J, using this criterion to establish an ''optimal'' cutpoint unnecessarily introduces an increased rate of misclassification.
